We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+9.32%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$871M
AUM Growth
+$56.2M
Cap. Flow
+$80.3M
Cap. Flow %
9.22%
Top 10 Hldgs %
80.56%
Holding
31
New
7
Increased
6
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$56.4M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$47M
3
RXDX
Ignyta, Inc.
RXDX
+$24.3M
4
RDUS
Radius Health, Inc.
RDUS
+$19M
5
AKBA icon
Akebia Therapeutics
AKBA
+$10.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.6M
2
LOXO
Loxo Oncology, Inc
LOXO
+$12.6M
3
ZGNX
Zogenix, Inc.
ZGNX
+$12.3M
4
NGNE icon
Neurogene
NGNE
+$11.3M
5
ARDX icon
Ardelyx
ARDX
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$155M 17.78%
5,580,690
+170,700
+3% +$4.51M
WVE icon
2
Wave Life Sciences
WVE
$1.12B
$132M 15.13%
7,088,651
– –
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$108M 12.35%
1,310,046
-315,165
-19% -$23.6M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$62.6M 7.18%
13,633,220
– –
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$61.2M 7.02%
+2,448,350
New +$56.4M
GTHX
6
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$46.8M 5.37%
+2,684,244
New +$47M
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
$41.6M 4.77%
4,016,990
+2,991,699
+292% +$24.3M
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$33.9M 3.89%
731,531
+26,830
+4% +$987K
MYOV
9
DELISTED
Myovant Sciences Ltd.
MYOV
$32.8M 3.77%
2,807,550
+459,128
+20% +$5.69M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.46B
$28.7M 3.29%
5,162,242
+1,672,447
+48% +$10.2M
RARX
11
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$25.3M 2.91%
1,351,808
– –
RDUS
12
DELISTED
Radius Health, Inc.
RDUS
$22.5M 2.58%
+497,157
New +$19M
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
$21.4M 2.45%
1,474,688
-976,549
-40% -$12.3M
NGNE icon
14
Neurogene
NGNE
$669M
$19.6M 2.25%
69,804
-39,398
-36% -$11.3M
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$18.7M 2.15%
+843,558
New +$6.64M
ACOR
16
DELISTED
Acorda Therapeutics
ACOR
$17.7M 2.04%
7,502
+3,420
+84% +$6.78M
AKBA icon
17
Akebia Therapeutics
AKBA
$338M
$12M 1.38%
+836,337
New +$10.6M
SGMO
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11M 1.26%
+1,250,000
New +$8.02M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.7M 0.88%
2,428,571
– –
TGTX icon
20
TG Therapeutics
TGTX
$8.34B
$7.04M 0.81%
700,000
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.35M 0.5%
591,070
– –
TARA icon
22
Protara Therapeutics
TARA
$217M
$2.04M 0.23%
+33,437
New +$1.87M
ARDX icon
23
Ardelyx
ARDX
$1.25B
– –
-828,283
Closed -$10.5M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.66B
– –
-636,248
Closed -$8.15M
ONC
25
BeOne Medicines Ltd
ONC
$34.2B
– –
-240,000
Closed -$8.79M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, RA Capital Management held 31 positions worth $871M, up 6.9% from $815M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

RA Capital Management deployed $80.3M of net new capital in Q2 2017, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 2,448,350 shares worth $61.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was AveXis, Inc. Common Stock, an estimated $23.6M trimmed.

  • RA Capital Management's largest Q2 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 2,448,350 shares worth $61.2M.
  • RA Capital Management added most to Ignyta, Inc. in Q2 2017, an estimated $24.3M increase.
  • RA Capital Management's biggest Q2 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $23.6M.
  • RA Capital Management fully exited Loxo Oncology, Inc in Q2 2017, selling an estimated $12.6M.
  • RA Capital Management's ten largest holdings make up 81% of its $871M portfolio in Q2 2017.
  • RA Capital Management opened 7 new positions and closed 9 in Q2 2017.
  • RA Capital Management's portfolio value rose 6.9% quarter-over-quarter to $871M.

Based on RA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.